Avid Bioservices, Inc.
Avid Bioservices, Inc. (CDMO) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
cdmo · pe ratio · data through Apr 30, 2024
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Avid Bioservices, Inc. (CDMO) measures how much investors pay for each dollar of the company's trailing earnings. CDMO's current PE ratio of N/A is calculated by dividing its stock price of $12.49 by its TTM earnings per share of -$2.23.
Source: FMP · /ratios-ttm · /analyst-estimates · 2024-04-30
PE Ratio History
2005 – 2024 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
Historical PE Range
Past 3 fiscal years · Front-end computedMinQ1 · 25%111.2x
MedianQ3 · 75%1974.8x
Max
At N/A, CDMO's current P/E is lower than in 0% of its annual fiscal year readings over the past 3 years — historically low.
Percentile calculated from annual fiscal year data points, not by trading day. Years where PE ≤ 0 or > 9,999 are excluded.
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Avid Bioservices, Inc.You CDMO | $799M | N/A | — | -$2.23 |
 Albireo Pharma, Inc. ALBO | $916M | N/A | — | -$7.87 |
 ASLAN Pharmaceuticals Limited ASLN | $777M | N/A | — | -$10.75 |
 Chimerix, Inc. CMRX | $801M | N/A | — | -$0.99 |
 Exscientia plc EXAI | $633M | N/A | — | -$1.18 |
 Harpoon Therapeutics, Inc. HARP | $865M | N/A | — | -$20.24 |
 Intercept Pharmaceuticals, Inc. ICPT | $795M | 3.63x | — | $3.41 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2024-04-30Latest FY2024 | — | $-2.23 | — | |
2023-04-30 FY2023 | 1974.79x | $0.01 | +30365.5% | |
2022-04-30 FY2022 | 6.48x | $2.08 | -94.2% | |
2021-04-30 FY2021 | 111.15x | $0.19 | — | |
2020-04-30 FY2020 | — | $-0.13 | — | |
2019-04-30 FY2019 | — | $-0.08 | — | |
2018-04-30 FY2018 | — | $-0.46 | — | |
2017-04-30 FY2017 | — | $-0.76 | — | |
2016-04-30 FY2016 | — | $-1.80 | — | |
2015-04-30 FY2015 | — | $-1.93 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Avid Bioservices, Inc. (CDMO) measures how much investors pay for each dollar of the company's trailing earnings. CDMO's current PE ratio of N/A is calculated by dividing its stock price of $12.49 by its TTM earnings per share of -$2.23.
Frequently asked questions
CDMO pe ratio · 6 questionsCDMO's current PE ratio is N/A as of 2026-06-09, based on a stock price of $12.49 and TTM EPS of -$2.23. Data sourced from Financial Modeling Prep via CDMO's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Avid Bioservices, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09